Business Context and Reporting Period
Company: Drugs Made In America Acquisition II Corp.
Filing Type: Form 8-K (Current Report)
Date of Report: March 6, 2026
Context: The Company is a Cayman Islands-based special purpose acquisition company (SPAC) with securities trading on The Nasdaq Stock Market LLC. This filing addresses "Irregularities" involving improper withdrawals from the Company's working capital account by the sponsor between September 26, 2025, and December 31, 2025.
Key Financial Metrics
- Trust Account Balance: Approximately $507,841,957 as of March 6, 2026.
- Working Capital: Subject to improper withdrawals (Irregularities); specific remaining balance not disclosed in this text.
- Revenue, Profit, Cash Flow, Margins, Debt: The filing text does not provide clear values for these operational metrics.
Material Changes and Events
The primary material event is the confirmation of improper withdrawals from the working capital account by the sponsor. The Board of Directors has confirmed that these irregularities did not extend to the Trust Account. The Trust Account balance remains intact at approximately $507.8 million.
Outlook, Risks, and Management Commentary
Management Action: The Board of Directors immediately took action to verify the scope of the irregularities upon discovery.
Risks: The filing highlights governance risks related to sponsor conduct and working capital management. While the Trust Account is confirmed secure, the integrity of the working capital account is compromised.
Guidance: No forward-looking financial guidance or business outlook is provided in this filing.
Investor Verification Checklist
- Verify the exact amount of funds withdrawn from the working capital account and the timeline of the irregularities.
- Confirm whether the sponsor has remediated the working capital shortfall or if the Company intends to seek reimbursement.
- Review the Company's internal controls and governance procedures to prevent future irregularities.
- Assess the impact of these events on the Company's ability to complete a business combination or liquidate.